A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

第3相 実施中（募集終了） NCT04548999

概要

This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.

Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)

Up to approximately 4.5 years · weeks

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of — Mapi Pharma Ltd.
• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patient — Genzyme, a Sanofi Company
• A Study of Oxidative Pathways in MS Fatigue — University of California, San Francisco
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
• Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Bioma — Gregory Wu
• Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral — Shionogi

すべての治験